AbCellera Results Presentation Deck

FINANCIALS Q2 2023 BUSINESS UPDATE COPYRIGHT © ABCELLERA 9 9 molecules in the clinic. MOLECULE bamlanivimab (LY-CoV555) bebtelovimab (LY-CoV1404) TAK-920/DNL919 undisclosed undisclosed NBL-012 NBL-015/FL-301 NBL-020 IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Marketed, Emergency Use Authorization (EUA) Phase 1 Phase 1 Phase 1 Phase 1 Phase 1 IND/CTA authorized Clinical field study THERAPEUTIC AREA ● ● ● infectious disease: COVID-19 ● infectious disease: COVID-19 neurology: Alzheimer's Disease neuroscience undisclosed dermatology gastrointestinal disease immunology • oncology oncology animal health PARTNER Lilly DENALI teva undisclosed NovaRock BOTHERAPEUTICS Invetx PROGRAM TYPE AbCellera pre-partnered program PARTNERED AbCellera partner-initiated discovery Trianni license AbCellera partner-initiated discovery As of June 30, 2023

View entire presentation